Acelyrin, Inc. (NASDAQ:SLRN) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 3.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,189,027 shares of the company’s stock after purchasing an additional 116,847 shares during the period. Vanguard Group Inc. owned about 3.28% of Acelyrin worth $32,432,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. venBio Partners LLC bought a new stake in shares of Acelyrin during the 2nd quarter valued at about $80,616,000. FMR LLC boosted its stake in Acelyrin by 20.2% in the third quarter. FMR LLC now owns 8,961,726 shares of the company’s stock valued at $89,914,000 after acquiring an additional 1,505,488 shares during the period. Kynam Capital Management LP bought a new position in shares of Acelyrin during the third quarter valued at approximately $12,204,000. Alliancebernstein L.P. acquired a new stake in shares of Acelyrin during the 2nd quarter worth approximately $23,894,000. Finally, Woodline Partners LP bought a new stake in shares of Acelyrin in the 2nd quarter worth approximately $21,643,000. 87.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SLRN. Wells Fargo & Company upped their price objective on Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 21st. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Acelyrin in a research report on Monday, April 1st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.67.

Acelyrin Stock Performance

Shares of SLRN stock opened at $5.76 on Friday. The firm has a market capitalization of $566.58 million and a PE ratio of -0.54. Acelyrin, Inc. has a 1 year low of $5.53 and a 1 year high of $29.88. The stock has a fifty day moving average of $7.54 and a two-hundred day moving average of $7.99.

Insider Activity at Acelyrin

In related news, CEO Shao-Lee Lin sold 15,701 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $7.60, for a total value of $119,327.60. Following the completion of the transaction, the chief executive officer now owns 1,587,335 shares in the company, valued at approximately $12,063,746. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.